SHR-1603
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 22, 2021
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
(clinicaltrials.gov)
- P1; N=128; Suspended; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Suspended
Clinical • Trial suspension • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1